Understanding (non)-adherence to the World Anti-Doping Code in athletics: Building capacity and amplifying voices in Ethiopia and Kenya
By
Investigateur principal
L.
Patterson
Leeds Beckett University
Royaume-Uni
―
2023
―
En vigueur
Sommaire
The project aims to aid AIU by investigating (non-) adherence to the World Anti[1]Doping Code (WADC) in Kenya and Ethiopia through a systematic consideration of the lived experience of athletes, athlete support personnel (ASP) and anti[1]doping/sporting organization staff. By amplifying African voices in track and field and road running, this project will offer unique insights into geographical regions that are under-served in anti-doping research.
An empirical investigation of moral values and attitudes in the context of clean sport behaviors
By
Investigateur principal
L.
Lazuras
Sheffield Hallam University
Royaume-Uni
―
2023
―
En vigueur
Sommaire
The project aims to advance scientific knowledge and understanding about the role of sport-specific values in fostering moral attitudes and emotions towards doping, and accordingly inform values-based education practices. The project’s objective is to adapt the Values & Moral Attitudes Model.
The role of coaches and parents in promoting anti-doping among the youth in grassroot sports in Kenya
By
Investigateur principal
J.
Kamenju
University of Nairobi
Kenya
―
2023
―
En vigueur
Sommaire
The study will examine the role of coaches and parents in promoting anti–doping behaviors among the youth in grassroots sports, investigating knowledge, attitudes of this population, while also exploring predictive factors of doping that can be influenced by education programs.
A qualitative exploration of athletes' lives, support needs and solutions after an anti-doping violation
By
Investigateur principal
C.
Blank
UMIT TIROL
Autriche
―
2023
―
En vigueur
Sommaire
A two-phase project examining athletes' experiences following an Adverse Analytical Finding and Anti-Doping Rule Violation. Phase one will use athlete researchers to interview sanctioned athletes. The results will inform phase two, a community based Participatory Research (CBPR) approach discuss how the relationship of sanctioned athletes to sport, clean sport and anti-doping is shaped and how rehabilitation and space for reparation can be incorporated into anti-doping.
Tramadol excretion study administered orally for the improvement of detection of these substances in anti-doping controls (analytical part)
By
Investigateur principal
R.
Ventura
Institut Municipal d’Investigacio Medica (IMIM)
Espagne
―
2022
―
En vigueur
Sommaire
Code: T22M01RTRV - Part 2
12 hours starting from any dose”, which is considered as the cut-off between maximal therapeutic dosagesfor athletes benefiting from a therapeutic use exemption and doses at which a doping effect could begin to be expected from systemic exposure [8]. The WADA established a urinary concentration
Tramadol excretion study administered orally for the improvement of detection of these substances in anti-doping controls (clinical part)
By
Investigateur principal
R.
de la Torre
Institut Municipal d’Investigacio Medica (IMIM)
Espagne
―
2022
―
En vigueur
Sommaire
Code: T22M01RTRV - Part 1
Salbutamolwas included in the prohibited list of the World Anti-Doping Agency (WADA) in 2004. While systemic salbutamol is banned, inhaled salbutamol is permitted but with dosage regimen restrictions. The dose should indeed not exceed “1600 µg over 24 hours in divided doses not to exceed 800 µg over.
Studies of glucocorticoids after oral administration: evaluation of reporting levels and washout periods
By
Investigateur principal
R.
Ventura
Institut Municipal d’Investigacio Medica (IMIM)
Espagne
―
2020
―
En vigueur
Sommaire
Code: T20M03RV
Recent research has demonstrated that the criterion of discrimination between allowed and prohibited administrations of GCs needs to be compound specific. For some GCs, largely detected in doping controls, no sufficient data is available, and the objective of this project is to perform excretion studies with these GCs to generate the data needed to define the reporting levels and the washout periods.
The project will be focused on dexamethasone (DEX), methylprednisolone (MP) and deflazacort (DEF).
The research will be focused on the following specific objectives:
To perform excretion studies of DEX, MP and DEF with administration of one single oral dose. For DEX, multiple oral doses will be also studied.
To measure concentrations in urine of the parent compounds and the main metabolite in case of DEF, to evaluate the reporting lebels and washout periods.
To measure concentrations of the compounds and cortisol in plasma, to evalulate the concordance of the urinary reporting levels and washout periods proposed with plasma concentrations of the active drug and the systemic effect
Establishing and optimizing hGH capture antibody-coated assay microplates as solid phases for the CMZ Differential Immunoassays for hGH Isoforms (CMZ hGH LIA)
By
Investigateur principal
D.
Müller
CMZ-ASSAY GMBH
Allemagne
―
2020
―
En vigueur
Sommaire
Code: T20M02DM
The differential immunoassays to detect doping with recombinant human growth hormone (hGH) have been in use at WADA accredited laboratories for more than 10 years now. From the beginning, the assays were produced in the coated tube (CT) format. In the past, this format, where the specific antibodies are coated to plastic tubes, and the final assay signal is determined by a tube luminometer, was very popular for immunoassays used in laboratory medicine and research applications. However, it meanwhile has been largely abandoned, and the respective assays were switched to the so-called microtiter plate (MTP) format. Here, the antibodies are coated to 96 wells of a plastic plate, and the final assay signal is read by a plate luminometer. The microplate format has advantages in terms of production, but also in terms of workflow in the laboratory. As a consequence of the grossly reduced use of CT assays in laboratories worldwide, production capacities for such CT assays become rare, and might become unavailable in the near future. To ensure continued production and availability of the differential immunoassays it is suggested to convert these assays to the MTP format now. While assay ingredients (and particularly the monoclonal antibodies involved) remain unaffected by the conversion to the MTP format, and it has been demonstrated for many assays used in clinical routine that key parameters such as assay specificity, linearity, reproducibility etc. remain unaffected by the change, the MTP format nevertheless has to be optimized and validated for each individual assay. The current project aims to establish the MTP format for the differential immunoassays.